83 results on '"Childs, R"'
Search Results
2. The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study
- Author
-
Ames, N. J., Barb, J. J., Ranucci, A., Kim, H., Mudra, S. E., Cashion, A. K., Townsley, D. M., Childs, R., Paster, B. J., Faller, L. L., and Wallen, G. R.
- Published
- 2019
- Full Text
- View/download PDF
3. Chapter: Multi-piloted operations
- Author
-
Martinez, Alan, primary, Childs, R. Joseph, additional, and Sutliff, Dan, additional
- Published
- 2019
- Full Text
- View/download PDF
4. Student Achievement at CCCU-Member Colleges: A Comparison of CCCU Students' Outcomes on the Uniform CPA Exam to Students' Outcomes at AACSB and Other Institutions of Higher Education
- Author
-
Hahn, William, Fairchild, Chris, and Childs, R. Joseph
- Abstract
This study investigated differences in Uniform Certified Public Accountant Exam (UCPAE) pass rates between candidates who graduated from Council for Christian Colleges & Universities member schools (CCCU-member) and candidates who graduated from institutions that are not CCCU members. The data set included 1,131 institutions (72,453 candidates) with reported 2012 UCPAE pass rates. CCCU-member schools were compared to schools accredited by the Association to Advance Collegiate Schools of Business (AACSB) as well as to schools that were not accredited by the AACSB. A Mann-Whitney "U" test revealed that there is no statistically significant difference in pass rates between CCCU-member schools and schools with AACSB accreditation, but revealed a statistically significant performance advantage favoring CCCU-member schools compared to schools without AACSB accreditation. This finding suggests that CCCU-member schools are preparing candidates for the UCPAE as proficiently as are AACSB-accredited institutions. They do so by incorporating a faith-based learning environment that employs teaching methods and student-faculty interaction in ways that prepare students for professional success while serving Christ.
- Published
- 2015
- Full Text
- View/download PDF
5. Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation
- Author
-
McDuffee, E, Aue, G, Cook, L, Ramos-Delgado, C, Shalabi, R, Worthy, T, Vo, P, and Childs, R W
- Published
- 2017
- Full Text
- View/download PDF
6. Compassionate use of remdesivir for patients with severe Covid-19
- Author
-
Grein, J, Ohmagari, N, Shin, D, Diaz, G, Asperges, E, Castagna, A, Feldt, T, Green, G, Green, M, Lescure, F, Nicastri, E, Oda, R, Yo, K, Quiros-Roldan, E, Studemeister, A, Redinski, J, Ahmed, S, Bernett, J, Chelliah, D, Chen, D, Chihara, S, Cohen, S, Cunningham, J, D'Arminio Monforte, A, Ismail, S, Kato, H, Lapadula, G, L'Her, E, Maeno, T, Majumder, S, Massari, M, Mora-Rillo, M, Mutoh, Y, Nguyen, D, Verweij, E, Zoufaly, A, Osinusi, A, Dezure, A, Zhao, Y, Zhong, L, Chokkalingam, A, Elboudwarej, E, Telep, L, Timbs, L, Henne, I, Sellers, S, Cao, H, Tan, S, Winterbourne, L, Desai, P, Mera, R, Gaggar, A, Myers, R, Brainard, D, Childs, R, Flanigan, T, Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., Feldt T., Green G., Green M. L., Lescure F. -X., Nicastri E., Oda R., Yo K., Quiros-Roldan E., Studemeister A., Redinski J., Ahmed S., Bernett J., Chelliah D., Chen D., Chihara S., Cohen S. H., Cunningham J., D'Arminio Monforte A., Ismail S., Kato H., Lapadula G., L'Her E., Maeno T., Majumder S., Massari M., Mora-Rillo M., Mutoh Y., Nguyen D., Verweij E., Zoufaly A., Osinusi A. O., DeZure A., Zhao Y., Zhong L., Chokkalingam A., Elboudwarej E., Telep L., Timbs L., Henne I., Sellers S., Cao H., Tan S. K., Winterbourne L., Desai P., Mera R., Gaggar A., Myers R. P., Brainard D. M., Childs R., Flanigan T., Grein, J, Ohmagari, N, Shin, D, Diaz, G, Asperges, E, Castagna, A, Feldt, T, Green, G, Green, M, Lescure, F, Nicastri, E, Oda, R, Yo, K, Quiros-Roldan, E, Studemeister, A, Redinski, J, Ahmed, S, Bernett, J, Chelliah, D, Chen, D, Chihara, S, Cohen, S, Cunningham, J, D'Arminio Monforte, A, Ismail, S, Kato, H, Lapadula, G, L'Her, E, Maeno, T, Majumder, S, Massari, M, Mora-Rillo, M, Mutoh, Y, Nguyen, D, Verweij, E, Zoufaly, A, Osinusi, A, Dezure, A, Zhao, Y, Zhong, L, Chokkalingam, A, Elboudwarej, E, Telep, L, Timbs, L, Henne, I, Sellers, S, Cao, H, Tan, S, Winterbourne, L, Desai, P, Mera, R, Gaggar, A, Myers, R, Brainard, D, Childs, R, Flanigan, T, Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., Feldt T., Green G., Green M. L., Lescure F. -X., Nicastri E., Oda R., Yo K., Quiros-Roldan E., Studemeister A., Redinski J., Ahmed S., Bernett J., Chelliah D., Chen D., Chihara S., Cohen S. H., Cunningham J., D'Arminio Monforte A., Ismail S., Kato H., Lapadula G., L'Her E., Maeno T., Majumder S., Massari M., Mora-Rillo M., Mutoh Y., Nguyen D., Verweij E., Zoufaly A., Osinusi A. O., DeZure A., Zhao Y., Zhong L., Chokkalingam A., Elboudwarej E., Telep L., Timbs L., Henne I., Sellers S., Cao H., Tan S. K., Winterbourne L., Desai P., Mera R., Gaggar A., Myers R. P., Brainard D. M., Childs R., and Flanigan T.
- Abstract
BACKGROUND Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. METHODS We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. RESULTS Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. CONCLUSIONS In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy.
- Published
- 2020
7. Optimization of Intrabone Delivery of Hematopoietic Progenitor Cells in a Swine Model Using Cell Radiolabeling with [89]zirconium
- Author
-
Pantin, J. M., Hoyt, R. F., Jr., Aras, O., Sato, N., Chen, M. Y., Hunt, T., Clevenger, R., Eclarinal, P., Adler, S., Choyke, P., and Childs, R. W.
- Published
- 2015
- Full Text
- View/download PDF
8. Subclinical hypernatraemia in a population of endurance racing sled dogs
- Author
-
Frye, C.W., primary, Goggs, R., additional, Childs, R., additional, Poplarski, J., additional, Hannon, M.B., additional, and Wakshlag, J.J., additional
- Published
- 2021
- Full Text
- View/download PDF
9. Hexaviral specific T-cells targeting parainfluenza, CMV, EBV, adenovirus, HHV6 and BKV used for prophylaxis and treatment of viral infections in patients post stem cell transplant
- Author
-
Keller, M.D., primary, Harris, K., additional, Hanley, P., additional, Abraham, A., additional, Davila, B.J., additional, Zhang, N., additional, Sani, G., additional, Lang, H., additional, Childs, R., additional, Jones, R., additional, and Bollard, C., additional
- Published
- 2019
- Full Text
- View/download PDF
10. Human natural killer cell manufacturing using a closed system process for patients with metastatic solid tumors or hematologic malignancies
- Author
-
Jin, J., primary, Reger, R., additional, Panch, S., additional, Childs, R., additional, Stroncek, D., additional, and Highfill, S.L., additional
- Published
- 2019
- Full Text
- View/download PDF
11. Gale Researcher Guide For: Fractional Reserve Banking
- Author
-
Childs, R. Joseph and Childs, R. Joseph
- Abstract
Gale Researcher Guide for: Fractional Reserve Banking is selected from Gale's academic platform Gale Researcher. These study guides provide peer-reviewed articles that allow students early success in finding scholarly materials and to gain the confidence and vocabulary needed to pursue deeper research.
- Published
- 2018
12. O-Glycome beam search arrays for carbohydrate ligand discovery
- Author
-
Li, Z, Gao, C, Zhang, Y, Palma, A, Childs, R, Silva, L, Liu, Y, Jiang, X, Chai, W, Feizi, T, and Wellcome Trust
- Subjects
O-glycan ,Rotaviruse ,Biochemistry & Molecular Biology ,Tandem Mass Spectrometry ,Viruses ,MD Multidisciplinary ,Omics ,Sequencing MS ,Thin Layer Chromatography ,Array analysis - Abstract
O-glycosylation is a post-translational modification of proteins crucial to molecular mechanisms in health and disease. O-glycans are typically highly heterogeneous. The involvement of specific O-glycan sequences in many bio-recognition systems is yet to be determined due to a lack of efficient methodologies. We describe here a targeted microarray approach: O-glycome beam search that is both robust and efficient for O-glycan ligand-discovery. Substantial simplification of the complex O-glycome profile and facile chromatographic resolution is achieved by arraying O-glycans as branches, monitoring by mass spectrometry, focusing on promising fractions, and on-array immuno-sequencing. This is orders of magnitude more sensitive than traditional methods. We have applied beam search approach to porcine stomach mucin and identified extremely minor components previously undetected within the O-glycome of this mucin that are ligands for the adhesive proteins of two rotaviruses. The approach is applicable to O-glycome recognition studies in a wide range of biological settings to give insights into glycan recognition structures in natural microenvironments.
- Published
- 2017
13. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- Author
-
Amiel, Stephanie, Aschner, Pablo, Childs R N, Belinda, Cryer, Philip E., de Galan, Bastiaan E., Heller, Simon R., Frier, Brian M., Gonder-Frederick, Linda, Jones, Timothy, Khunti, Kamlesh, Leiter, Lawrence A., McCrimmon, Rory J., Luo, Yingying, Seaquist, Elizabeth R., Vigersky, Robert, and Zoungas, Sophia
- Subjects
Position statement ,medicine.medical_specialty ,Plasma Glucose Concentration ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,education ,030209 endocrinology & metabolism ,Severe Hypoglycaemia ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Glucose Concentration ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,030212 general & internal medicine ,Pure autonomic failure ,Position Statement ,Hypoglycemia unawareness ,American diabetes association ,business.industry ,nutritional and metabolic diseases ,medicine.disease ,Clinical trial ,Endocrinology ,Continuous Glucose Monitoring ,American Diabetes Association ,business - Abstract
Position Statement\ud \ud The International Hypoglycaemia Study Group recommends that the frequency of detection of a glucose concentration
- Published
- 2017
- Full Text
- View/download PDF
14. A phase I study of HERV-E TCR transduced autologous T Cells (HERV-E TCR T Cells) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)
- Author
-
Nadal, R., primary, Cherkasova, E., additional, Barisic, S., additional, Granadier, D., additional, Aue, G., additional, Wells, B., additional, Hawks, G., additional, Hughes, T., additional, Shalabi, R., additional, Stroncek, D., additional, Highfill, S., additional, Scurti, G., additional, Chen, L., additional, Reger, R., additional, Nishimura, M., additional, and Childs, R., additional
- Published
- 2018
- Full Text
- View/download PDF
15. 924TiP - A phase I study of HERV-E TCR transduced autologous T Cells (HERV-E TCR T Cells) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)
- Author
-
Nadal, R., Cherkasova, E., Barisic, S., Granadier, D., Aue, G., Wells, B., Hawks, G., Hughes, T., Shalabi, R., Stroncek, D., Highfill, S., Scurti, G., Chen, L., Reger, R., Nishimura, M., and Childs, R.
- Published
- 2018
- Full Text
- View/download PDF
16. Conditioning with rabbit versus horse ATG dramatically alters clinical outcomes in identical twins with severe aplastic anemia transplanted with the same allogeneic donor
- Author
-
Vo, P. T., primary, Pantin, J., additional, Ramos, C., additional, Cook, L., additional, Cho, E., additional, Kurlander, R., additional, Khuu, H., additional, Barrett, J., additional, Leitman, S., additional, and Childs, R. W., additional
- Published
- 2015
- Full Text
- View/download PDF
17. A difficult relationship.
- Author
-
CHILDS, R. MICHAEL
- Subjects
- *
INTERNATIONAL economic relations ,IRANIAN foreign relations, 1997- - Abstract
A letter to the editor is presented in response to the article "Hiyatollah" which was published in the July 18, 2015 issue.
- Published
- 2015
18. Compassionate Use of Remdesivir for Patients with Severe Covid-19
- Author
-
Jennifer Cunningham, Marta Mora-Rillo, Robert P. Myers, Gary M. Green, Polly Desai, Toshitaka Maeno, Antonella D’Arminio Monforte, Yoshikazu Mutoh, Emanuele Nicastri, Ilana Henne, Susanna K. Tan, Erika Asperges, Jonathan Grein, Saad Ismail, Alex Studemeister, Rentaro Oda, Anuj Gaggar, Anu Osinusi, Kikuo Yo, Erwan L’Her, Huyen Cao, Hideaki Kato, Duc Nguyen, Seema Ahmed, Daniel Shin, Marco Massari, John Redinski, Giuseppe Lapadula, Lijie Zhong, Shingo Chihara, Laura Telep, Alexander Zoufaly, Daniel Chelliah, Ewa Verweij, Timothy Flanigan, Lucinda Winterbourne, Robertino Mera, Eugenia Quiros-Roldan, Diana M. Brainard, Adam DeZure, Leighann Timbs, Norio Ohmagari, Stuart H. Cohen, Sumit Majumder, Richard Childs, François-Xavier Lescure, Jorge Bernett, Emon Elboudwarej, Yang Zhao, Anand Chokkalingam, Scott Sellers, George Diaz, Torsten Feldt, Margaret L. Green, Danny Chen, Antonella Castagna, Grein, J, Ohmagari, N, Shin, D, Diaz, G, Asperges, E, Castagna, A, Feldt, T, Green, G, Green, M, Lescure, F, Nicastri, E, Oda, R, Yo, K, Quiros-Roldan, E, Studemeister, A, Redinski, J, Ahmed, S, Bernett, J, Chelliah, D, Chen, D, Chihara, S, Cohen, S, Cunningham, J, D'Arminio Monforte, A, Ismail, S, Kato, H, Lapadula, G, L'Her, E, Maeno, T, Majumder, S, Massari, M, Mora-Rillo, M, Mutoh, Y, Nguyen, D, Verweij, E, Zoufaly, A, Osinusi, A, Dezure, A, Zhao, Y, Zhong, L, Chokkalingam, A, Elboudwarej, E, Telep, L, Timbs, L, Henne, I, Sellers, S, Cao, H, Tan, S, Winterbourne, L, Desai, P, Mera, R, Gaggar, A, Myers, R, Brainard, D, Childs, R, Flanigan, T, Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F. -X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., Chen, D., Chihara, S., Cohen, S. H., Cunningham, J., D'Arminio Monforte, A., Ismail, S., Kato, H., Lapadula, G., L'Her, E., Maeno, T., Majumder, S., Massari, M., Mora-Rillo, M., Mutoh, Y., Nguyen, D., Verweij, E., Zoufaly, A., Osinusi, A. O., Dezure, A., Zhao, Y., Zhong, L., Chokkalingam, A., Elboudwarej, E., Telep, L., Timbs, L., Henne, I., Sellers, S., Cao, H., Tan, S. K., Winterbourne, L., Desai, P., Mera, R., Gaggar, A., Myers, R. P., Brainard, D. M., Childs, R., and Flanigan, T.
- Subjects
Compassionate Use Trials ,Male ,viruses ,030204 cardiovascular system & hematology ,Pharmacology ,Medical and Health Sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Japan ,80 and over ,Medicine ,030212 general & internal medicine ,Viral ,Lung ,Polymerase ,Aged, 80 and over ,Alanine ,biology ,Respiration ,General Medicine ,Prodrug ,Middle Aged ,humanities ,Europe ,Infectious Diseases ,6.1 Pharmaceuticals ,Artificial ,Administration ,Original Article ,Administration, Intravenous ,Female ,Intravenous ,Coronavirus Infections ,Human ,Adenosine monophosphate ,United State ,Adult ,Canada ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Clinical Trials and Supportive Activities ,Pneumonia, Viral ,Administration, Intravenou ,Antiviral Agents ,03 medical and health sciences ,Betacoronavirus ,Young Adult ,Clinical Research ,General & Internal Medicine ,Humans ,Pandemics ,Aged ,Antiviral Agent ,Betacoronaviru ,Pandemic ,business.industry ,Coronavirus Infection ,SARS-CoV-2 ,Prevention ,Compassionate Use ,Evaluation of treatments and therapeutic interventions ,COVID-19 ,Pneumonia ,Respiration, Artificial ,In vitro ,Adenosine Monophosphate ,United States ,COVID-19 Drug Treatment ,Coronavirus ,Emerging Infectious Diseases ,Good Health and Well Being ,chemistry ,biology.protein ,business - Abstract
Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. Results Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. Conclusions In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)
- Published
- 2020
19. Occurrence and development of folding related to normal faulting within a mechanically heterogeneous sedimentary sequence: A case study from Inner Moray Firth, UK
- Author
-
Lapadat A., Imber J., Yielding G., Iacopini D., McCaffrey K. J. W., Long J. J., Jones R. R., C. Childs, R. E. Holdsworth, C. A.-L. Jackson, T. Manzocchi, J. J. Walsh, and G. Yielding, Lapadat, A., Imber, J., Yielding, G., Iacopini, D., Mccaffrey, K. J. W., Long, J. J., and Jones, R. R.
- Published
- 2017
20. Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation.
- Author
-
Vo P, Srinivasan R, Purev E, McDuffee E, Worthy T, Shalabi R, Wood K, Wells B, Reger R, Stroncek D, Geller N, Aue G, Tian X, and Childs R
- Abstract
Competing Interests: Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: All participants signed written informed-consent forms. The authors have obtained informed consent for publication of the images. The study was approved by the NHLBI Institutional Review Board. All procedures were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was registered in ClinicalTrials.gov (NCT00047060).
- Published
- 2024
- Full Text
- View/download PDF
21. Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infection.
- Author
-
Huapaya JA, Gairhe S, Kanth S, Tian X, Demirkale CY, Regenold D, Sun J, Lynch NF, Luo R, Forsberg A, Dewar R, Rehman T, Li W, Krack J, Kuruppu J, Aboye EA, Barnett C, Strich JR, Davey R, Childs R, Chertow D, Kovacs JA, Torabi-Parizi P, and Suffredini AF
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Prospective Studies, COVID-19 Vaccines immunology, Vaccination, Aged, Severity of Illness Index, Blood Proteins metabolism, Blood Proteins analysis, COVID-19 immunology, COVID-19 blood, Proteome, SARS-CoV-2 immunology
- Abstract
Background: Limited data are available describing the effects of SARS-CoV-2 breakthrough infections on the plasma proteome., Methods: PCR-positive SARS-CoV-2 patients, enrolled in a natural history study, underwent analysis of the plasma proteome. A prospective cohort of 66 unvaccinated and 24 vaccinated persons with different degrees of infection severity were evaluated acutely (within 40 days of symptom onset), and at three and ten months. Comparisons based on vaccination status alone and unsupervised hierarchical clustering were performed. A second cohort of vaccinated Omicron patients were evaluated acutely and at ten months., Results: Acutely, unvaccinated patients manifested overexpression of proteins involved in immune and inflammatory responses, while vaccinated patients exhibited adaptive immune responses without significant inflammation. At three and ten months, only unvaccinated patients had diminished but sustained inflammatory (C3b, CCL15, IL17RE) and immune responses (DEFA5,TREM1). Both groups had underexpression of pathways essential for cellular function, signaling, and angiogenesis (AKT1, MAPK14, HSPB1) across phases. Unsupervised clustering, based on protein expression, identified four groups of patients with variable vaccination rates demonstrating that additional clinical factors influence the plasma proteome. The proteome of vaccinated Omicron patients did not differ from vaccinated pre-Omicron patients., Conclusions: Vaccination attenuates the inflammatory response to SARS-CoV-2 infection across phases. However, at ten months after symptom onset, changes in the plasma proteome persist in both vaccinated and unvaccinated individuals, which may be relevant to post-acute sequelae of SARS-CoV-2 and other viral infections associated with post-acute infection syndromes., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Huapaya, Gairhe, Kanth, Tian, Demirkale, Regenold, Sun, Lynch, Luo, Forsberg, Dewar, Rehman, Li, Krack, Kuruppu, Aboye, Barnett, Strich, Davey, Childs, Chertow, Kovacs, Torabi-Parizi and Suffredini.)
- Published
- 2024
- Full Text
- View/download PDF
22. "Let's talk about sex, inflammaging, and cognition, baby": A meta-analysis and meta-regression of 106 case-control studies on mild cognitive impairment and Alzheimer's disease.
- Author
-
Childs R, Karamacoska D, Lim CK, and Steiner-Lim GZ
- Abstract
Background: Chronic inflammation is recognised as an important component of Alzheimer's disease (AD), yet its relationship with cognitive decline, sex-differences, and age is not well understood. This study investigated the relationship between inflammatory markers, cognition, sex, and age in individuals with mild cognitive impairment (MCI) and AD., Methods: A systematic review was performed to identify case-control studies which measured cognitive function and inflammatory markers in serum, plasma, and cerebrospinal fluid in individuals with MCI or AD compared with healthy control (HC) participants. Meta-analysis was performed with Hedges' g calculated in a random effects model. Meta-regression was conducted using age, sex, and mini-mental status exam (MMSE) values., Results: A total of 106 studies without a high risk of bias were included in the meta-analysis including 18,145 individuals: 5625 AD participants, 3907 MCI participants, and 8613 HC participants. Combined serum and plasma meta-analysis found that IL1β, IL6, IL8, IL18, CRP, and hsCRP were significantly raised in individuals with AD compared to HC. In CSF, YKL40, and MCP-1 were raised in AD compared to HC. YKL40 was also raised in MCI compared to HC. Meta-regression analysis highlighted several novel findings: MMSE was negatively correlated with IL6 and positively correlated with IL1α in AD, while in MCI studies, MMSE was negatively correlated with IL8 and TNFα. Meta-regression also revealed sex-specific differences in levels of IL1α, IL4, IL6, IL18, hsCRP, MCP-1, and YKL-40 across AD and MCI studies, and age was found to account for heterogeneity of CRP, MCP-1, and IL4 in MCI and AD., Conclusion: Elevated levels of IL6 and YKL40 may reflect microglial inflammatory activity in both MCI and AD. Systemic inflammation may interact with the central nervous system, as poor cognitive function in individuals with AD and MCI was associated with higher levels of serum and plasma proinflammatory cytokines IL6 and TNFα. Moreover, variations of systemic inflammation between males and females may be modulated by sex-specific hormonal changes, such as declining oestrogen levels in females throughout the menopause transition. Longitudinal studies sampling a range of biospecimen types are needed to elucidate the nuances of the relationship between inflammation and cognition in individuals with MCI and AD, and understand how systemic and central inflammation differentially impact cognitive function., Competing Interests: None., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
23. Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19.
- Author
-
Kanth SM, Huapaya JA, Gairhe S, Wang H, Tian X, Demirkale CY, Hou C, Ma J, Kuhns DB, Fink DL, Malayeri A, Turkbey E, Harmon SA, Chen MY, Regenold D, Lynch NF, Ramelli S, Li W, Krack J, Kuruppu J, Lionakis MS, Strich JR, Davey R, Childs R, Chertow DS, Kovacs JA, Parizi PT, and Suffredini AF
- Subjects
- Humans, Female, Male, Middle Aged, Longitudinal Studies, Adult, Bronchoalveolar Lavage Fluid chemistry, Aged, COVID-19 metabolism, COVID-19 pathology, COVID-19 virology, Proteome metabolism, Lung metabolism, Lung pathology, Lung diagnostic imaging, SARS-CoV-2 isolation & purification
- Abstract
In order to assess homeostatic mechanisms in the lung after COVID-19, changes in the protein signature of bronchoalveolar lavage from 45 patients with mild to moderate disease at three phases (acute, recovery, and convalescent) are evaluated over a year. During the acute phase, inflamed and uninflamed phenotypes are characterized by the expression of tissue repair and host defense response molecules. With recovery, inflammatory and fibrogenic mediators decline and clinical symptoms abate. However, at 9 months, quantified radiographic abnormalities resolve in the majority of patients, and yet compared to healthy persons, all showed ongoing activation of cellular repair processes and depression of the renin-kallikrein-kinin, coagulation, and complement systems. This dissociation of prolonged reparative processes from symptom and radiographic resolution suggests that occult ongoing disruption of the lung proteome is underrecognized and may be relevant to recovery from other serious viral pneumonias., Competing Interests: Declaration of interests The authors declare no competing interests., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
24. Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections.
- Author
-
Huapaya JA, Higgins J, Kanth S, Demirkale CY, Gairhe S, Aboye EA, Regenold D, Sahagun SJ, Pastor G, Swaim D, Dewar R, Rehman T, Highbarger HC, Lallemand P, Laverdure S, Adelsberger J, Rupert A, Li W, Krack J, Teferi G, Kuruppu J, Strich JR, Davey R, Childs R, Chertow D, Kovacs JA, Barnett C, Torabi-Parizi P, and Suffredini AF
- Subjects
- Humans, Female, SARS-CoV-2, Breakthrough Infections, Prospective Studies, Vaccination, COVID-19
- Abstract
Background: Data on cellular immune responses in persons with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following vaccination are limited. The evaluation of these patients with SARS-CoV-2 breakthrough infections may provide insight into how vaccinations limit the escalation of deleterious host inflammatory responses., Methods: We conducted a prospective study of peripheral blood cellular immune responses to SARS-CoV-2 infection in 21 vaccinated patients, all with mild disease, and 97 unvaccinated patients stratified based on disease severity., Results: We enrolled 118 persons (aged 50 years [SD 14.5 years], 52 women) with SARS-CoV-2 infection. Compared to unvaccinated patients, vaccinated patients with breakthrough infections had a higher percentage of antigen-presenting monocytes (HLA-DR+), mature monocytes (CD83+), functionally competent T cells (CD127+), and mature neutrophils (CD10+); and lower percentages of activated T cells (CD38+), activated neutrophils (CD64+), and immature B cells (CD127+CD19+). These differences widened with increased disease severity in unvaccinated patients. Longitudinal analysis showed that cellular activation decreased over time but persisted in unvaccinated patients with mild disease at 8-month follow-up., Conclusions: Patients with SARS-CoV-2 breakthrough infections exhibit cellular immune responses that limit the progression of inflammatory responses and suggest mechanisms by which vaccination limits disease severity. These data may have implications for developing more effective vaccines and therapies. Clinical Trials Registration. NCT04401449., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
- Published
- 2023
- Full Text
- View/download PDF
25. Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.
- Author
-
Migdady Y, Pang Y, Kalsi SS, Childs R, and Arai S
- Subjects
- ABO Blood-Group System, Blood Group Incompatibility complications, Humans, Anemia, Hemolytic, Autoimmune complications, Graft vs Host Disease etiology, Graft vs Host Disease therapy, Hematopoietic Stem Cell Transplantation adverse effects, Red-Cell Aplasia, Pure
- Abstract
Anemia after allogeneic hematopoietic stem cell transplantation (HSCT) can be immune or non-immune mediated. Auto- or alloimmunity resulting from blood group incompatibility remains an important cause in post-HSCT immune-mediated anemia. ABO incompatibility is commonly encountered in HSCT and may lead to serious clinical complications, including acute hemolysis, pure red cell aplasia, and passenger lymphocyte syndrome. It remains controversial whether ABO incompatibility may affect HSCT outcomes, such as relapse, nonrelapse mortality, graft-versus-host disease, and survival. Non-ABO incompatibility is less frequently encountered but can have similar complications to ABO incompatibility, causing adverse clinical outcomes. It is crucial to identify the driving etiology of post-HSCT anemia in order to prevent and treat this condition. This requires a comprehensive understanding of the mechanism of anemia in blood group-incompatible HSCT and the temporal association between HSCT and anemia. In this review, we summarize the literature on post-HSCT immune-mediated anemia with a focus on ABO and non-ABO blood group incompatibility, describe the underlying mechanism of anemia, and outline preventive and treatment approaches., (Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
- Author
-
Clara JA, Levy ER, Reger R, Barisic S, Chen L, Cherkasova E, Chakraborty M, Allan DSJ, and Childs R
- Subjects
- Animals, Cell Line, Tumor, Humans, Luciferases, Firefly, Mice, Mice, Inbred NOD, Transfection, ADP-ribosyl Cyclase 1 metabolism, CRISPR-Cas Systems immunology, Gene Editing methods, Immunotherapy methods, Killer Cells, Natural metabolism
- Abstract
Background: Adoptive transfer of natural killer (NK) cells with augmented antibody-dependent cellular cytotoxicity (ADCC) capabilities and resistance to CD38 targeting has the potential to enhance the clinical anti-myeloma activity of daratumumab (DARA). Therefore, we sought to develop an efficient CRISPR/Cas9-based gene editing platform to disrupt CD38 expression (CD38 knockout (KO)) in ex vivo expanded NK cells and simultaneously arm CD38
KO NK cells with a high-affinity CD16 (CD16-158V) receptor., Methods: CD38KO human NK cells were generated using Cas9 ribonucleoprotein complexes. The platform was expanded by incorporating messenger RNA (mRNA) transfection of CD38KO NK cells and targeted gene insertion at the CD38 locus to mediate gene knockin (KI). The capacity of these gene-edited NK cells to persist and mediate ADCC in the presence of DARA was tested in vitro and in a MM.1S xenograft mouse model., Results: Highly efficient CD38 gene disruption was achieved in ex vivo expanded NK cells without affecting their proliferative or functional capacity. CD38 KO conferred resistance to DARA-induced NK cell fratricide, enabling persistence and augmented ADCC against myeloma cell lines in the presence of DARA in vitro and in a MM.1S xenograft mouse model. CD38KO NK cells could be further modified by transfection with mRNA encoding a CD16-158V receptor, resulting in augmented DARA-mediated ADCC. Finally, we observed that a homology-directed repair template targeted to the CD38 locus facilitated an efficient 2-in-1 CD38 KO coupled with KI of a truncated CD34 reporter and CD16-158V receptor, with CD38KO /CD16KI NK cells demonstrating a further enhancement of DARA-mediated ADCC both in vitro and in vivo., Conclusions: Adoptive immunotherapy using ex vivo expanded CD38KO /CD16KI NK cells has the potential to boost the clinical efficacy of DARA. By incorporating complementary genetic engineering strategies into a CD38 KO manufacturing platform, we generated NK cells with substantially augmented CD38-directed antitumor activity, establishing a strong rationale for exploring this immunotherapy strategy in the clinic., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)- Published
- 2022
- Full Text
- View/download PDF
27. The effect of aging and chronic microglia activation on the morphology and numbers of the cerebellar Purkinje cells.
- Author
-
Childs R, Gamage R, Münch G, and Gyengesi E
- Subjects
- Aging metabolism, Animals, Dendritic Spines metabolism, Dendritic Spines ultrastructure, Glial Fibrillary Acidic Protein genetics, Inflammation metabolism, Interleukin-6 genetics, Mice, Microglia cytology, Purkinje Cells metabolism, Purkinje Cells pathology, Aging pathology, Glial Fibrillary Acidic Protein metabolism, Interleukin-6 metabolism, Microglia metabolism, Purkinje Cells cytology
- Abstract
Reduced cerebellar volume and motor dysfunction have previously been observed in the GFAP-IL6 murine model of chronic neuroinflammation. This study aims to extend these findings by investigating the effect of microglial activation and ageing on the total number of Purkinje cells and the morphology of their dendritic arborization. Through comparison of transgenic GFAP-IL6 mice and their wild-type counterparts at the ages of 12 and 24-months, we were able to investigate the effects of ageing and chronic microglial activation on Purkinje cells. Unbiased stereology was used to estimate the number of microglia in Iba1
+ stained tissue and Purkinje cells in calbindin stained tissue. Morphological analyses were made using 3D reconstructions of images acquired from the Golgi-stained cerebellar tissue. We found that the total number of microglia increased by approximately 5 times in the cerebellum of GFAP-IL6 mice compared to their WT littermates. The number of Purkinje cells decreased by as much as 50 % in aged wild type mice and 83 % in aged GFAP-IL6 mice. The remaining Purkinje cells in these cohorts were found to have significant reductions in their total dendritic length and number of branching points, indicating how the complexity of the Purkinje cell dendritic arbor reduces through age and inflammation. GFAP-IL6 mice, when compared to WT mice, had higher levels of microglial activation and more profound neurodegenerative changes in the cerebellum. The presence of constitutive IL6 production, driving chronic neuroinflammation, may account for these neurodegenerative changes in GFAP-IL6 mice., (Copyright © 2021 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
28. Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation.
- Author
-
Gamage R, Wagnon I, Rossetti I, Childs R, Niedermayer G, Chesworth R, and Gyengesi E
- Abstract
Aging is a complex biological process that increases the risk of age-related cognitive degenerative diseases such as dementia, including Alzheimer's disease (AD), Lewy Body Dementia (LBD), and mild cognitive impairment (MCI). Even non-pathological aging of the brain can involve chronic oxidative and inflammatory stress, which disrupts the communication and balance between the brain and the immune system. There has been an increasingly strong connection found between chronic neuroinflammation and impaired memory, especially in AD. While microglia and astrocytes, the resident immune cells of the central nervous system (CNS), exerting beneficial effects during the acute inflammatory phase, during chronic neuroinflammation they can become more detrimental. Central cholinergic circuits are involved in maintaining normal cognitive function and regulating signaling within the entire cerebral cortex. While neuronal-glial cholinergic signaling is anti-inflammatory and anti-oxidative, central cholinergic neuronal degeneration is implicated in impaired learning, memory sleep regulation, and attention. Although there is evidence of cholinergic involvement in memory, fewer studies have linked the cholinergic anti-inflammatory and anti-oxidant pathways to memory processes during development, normal aging, and disease states. This review will summarize the current knowledge of cholinergic effects on microglia and astroglia, and their role in both anti-inflammatory and anti-oxidant mechanisms, concerning normal aging and chronic neuroinflammation. We provided details on how stimulation of α7 nicotinic acetylcholine (α7nACh) receptors can be neuroprotective by increasing amyloid-β phagocytosis, decreasing inflammation and reducing oxidative stress by promoting the nuclear factor erythroid 2-related factor 2 (Nrf2) pathways and decreasing the release of pro-inflammatory cytokines. There is also evidence for astroglial α7nACh receptor stimulation mediating anti-inflammatory and antioxidant effects by inhibiting the nuclear factor-κB (NF-κB) pathway and activating the Nrf2 pathway respectively. We conclude that targeting cholinergic glial interactions between neurons and glial cells via α7nACh receptors could regulate neuroinflammation and oxidative stress, relevant to the treatment of several neurodegenerative diseases., (Copyright © 2020 Gamage, Wagnon, Rossetti, Childs, Niedermayer, Chesworth and Gyengesi.)
- Published
- 2020
- Full Text
- View/download PDF
29. Profiles of Co-Occurring Difficulties Identified Through School-Based Screening.
- Author
-
Aitken M, Martinussen R, Childs R, and Tannock R
- Subjects
- Child, Humans, Parents, Schools, Attention Deficit Disorder with Hyperactivity diagnosis, Attention Deficit Disorder with Hyperactivity epidemiology
- Abstract
Objective: This study used latent class analysis to identify patterns of co-occurrence among common childhood difficulties (inattention/hyperactivity, internalizing, externalizing, peer problems, and reading difficulties). Method: Parents and teachers of 501 children ages 6 to 9 provided mental health and social ratings, and children completed a reading task. Results: Four latent classes were identified in the analysis of parent ratings and reading: one with inattention/hyperactivity, externalizing, peer problems, and internalizing difficulties; one with inattention/hyperactivity and reading difficulties; one with internalizing and peer problems; and one normative class. The analysis of teacher ratings and reading also identified four latent classes: one with inattention/hyperactivity and externalizing, one with inattention/hyperactivity and reading difficulties, one with internalizing problems, and one normative class. Children in latent classes characterized by one or more difficulties were more impaired than children in the normative latent class 1 year later. Conclusion: The results highlight the need for multifaceted interventions.
- Published
- 2020
- Full Text
- View/download PDF
30. Compassionate Use of Remdesivir for Patients with Severe Covid-19.
- Author
-
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, and Flanigan T
- Subjects
- Adenosine Monophosphate adverse effects, Adenosine Monophosphate therapeutic use, Administration, Intravenous, Adult, Aged, Aged, 80 and over, Alanine adverse effects, Alanine therapeutic use, Antiviral Agents adverse effects, Betacoronavirus, COVID-19, Canada, Coronavirus Infections mortality, Europe, Female, Humans, Japan, Male, Middle Aged, Pandemics, Pneumonia, Viral mortality, Respiration, Artificial, SARS-CoV-2, United States, Young Adult, COVID-19 Drug Treatment, Adenosine Monophosphate analogs & derivatives, Alanine analogs & derivatives, Antiviral Agents therapeutic use, Compassionate Use Trials, Coronavirus Infections drug therapy, Pneumonia, Viral drug therapy
- Abstract
Background: Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2., Methods: We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day., Results: Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation., Conclusions: In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)., (Copyright © 2020 Massachusetts Medical Society.)
- Published
- 2020
- Full Text
- View/download PDF
31. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
- Author
-
Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA, Adams SD, Reger R, Aue G, Tian X, and Childs R
- Subjects
- Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized pharmacology, Female, Humans, Male, Middle Aged, Pilot Projects, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, HLA Antigens immunology, Immunization methods, Platelet Transfusion methods
- Abstract
Heavily transfused patients frequently develop human leukocyte antigen (HLA) allo-immunization resulting in platelet transfusion refractoriness and a high risk for life-threatening thrombocytopenia. Data suggest complement activation leading to the destruction of platelets bound by HLA allo-antibodies may play a pathophysiologic role in platelet refractoriness. Here we conducted a pilot trial to investigate the use of eculizumab, a monoclonal antibody that binds and inhibits C5 complement, to treat platelet transfusion refractoriness in allo-immunized patients with severe thrombocytopenia. A single eculizumab infusion was administered to 10 eligible patients, with four (40%) patients overcoming platelet refractories assessed measuring the corrected platelet count increment (CCI) 10-60 min and 18-24 h post transfusion. Responding patients had a reduction in the requirement for subsequent platelet transfusions and had higher post-transfusion platelet increments for 14 days following eculizumab administration. Remarkably, three of the four responders met CCI criteria for response despite receiving HLA-incompatible platelets. Our results suggest that eculizumab has the ability to overcome platelet transfusion refractoriness in patients with broad HLA allo-immunization. This study establishes proof of principle that complement inhibition can treat platelet transfusion refractoriness, laying the foundation for a large multicentre trial to assess the overall efficacy of this approach (ClinicalTrials.gov, identifier: NCT02298933)., (© 2020 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
32. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
- Author
-
Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, Tobin NP, Blake E, Seitz C, Thomas R, Wagner AK, Andersson J, de Boniface J, Bergh J, Murray S, Alici E, Childs R, Johansson M, Westerberg LS, Haglund F, Hartman J, and Lundqvist A
- Subjects
- 4-1BB Ligand immunology, GPI-Linked Proteins immunology, Humans, K562 Cells, Killer Cells, Natural pathology, Lymphocytes, Tumor-Infiltrating pathology, Neoplasms pathology, 5'-Nucleotidase immunology, Killer Cells, Natural immunology, Lymphocytes, Tumor-Infiltrating immunology, Neoplasm Proteins immunology, Neoplasms immunology, Tumor Escape, Tumor Microenvironment immunology
- Abstract
High levels of ecto-5'-nucleotidase (CD73) have been implicated in immune suppression and tumor progression, and have also been observed in cancer patients who progress on anti-PD-1 immunotherapy. Although regulatory T cells can express CD73 and inhibit T cell responses via the production of adenosine, less is known about CD73 expression in other immune cell populations. We found that tumor-infiltrating NK cells upregulate CD73 expression and the frequency of these CD73-positive NK cells correlated with larger tumor size in breast cancer patients. In addition, the expression of multiple alternative immune checkpoint receptors including LAG-3, VISTA, PD-1, and PD-L1 was significantly higher in CD73-positive NK cells than in CD73-negative NK cells. Mechanistically, NK cells transport CD73 in intracellular vesicles to the cell surface and the extracellular space via actin polymerization-dependent exocytosis upon engagement of 4-1BBL on tumor cells. These CD73-positive NK cells undergo transcriptional reprogramming and upregulate IL-10 production via STAT3 transcriptional activity, suppressing CD4-positive T cell proliferation and IFN-γ production. Taken together, our results support the notion that tumors can hijack NK cells as a means to escape immunity and that CD73 expression defines an inducible population of NK cells with immunoregulatory properties within the tumor microenvironment.
- Published
- 2020
- Full Text
- View/download PDF
33. Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy.
- Author
-
Reoma LB, Trindade CJ, Monaco MC, Solis J, Montojo MG, Vu P, Johnson K, Beck E, Nair G, Khan OI, Quezado M, Hewitt SM, Reich DS, Childs R, and Nath A
- Subjects
- Adolescent, Base Sequence, Brain Diseases diagnostic imaging, Fatal Outcome, Female, Humans, JC Virus isolation & purification, Nitriles, Pyrimidines, Brain Diseases drug therapy, Brain Diseases genetics, JC Virus genetics, Janus Kinases genetics, Pyrazoles therapeutic use
- Abstract
Objective: JC virus (JCV) infection is a lytic infection of oligodendrocytes in progressive multifocal leukoencephalopathy; less common forms of central nervous system manifestations associated with JCV infection include granule cell neuronopathy, encephalopathy, and meningitis. Presented is the first case of fatal JCV encephalopathy after immunosuppressive therapy that included ruxolitinib., Methods: Postmortem analysis included next generation sequencing, Sanger sequencing, tissue immunohistochemistry, and formalin-fixed hemisphere 7T magnetic resonance imaging., Results: JCV DNA isolated from postmortem tissue samples identified a novel 12bp insertion that altered the transcription site binding pattern in an otherwise "wild-type virus," which has long been thought to be the nonpathogenic form of JCV. Anti-VP1 staining demonstrated infection in cortical neurons, hippocampal neurons, and glial and endothelial cells., Interpretation: This expands the spectrum of identified JCV diseases associated with broad-spectrum immunosuppression, including JAK-STAT inhibitors, and sheds light on an additional neurotropic virus strain of the archetype variety. ANN NEUROL 2019;86:878-884., (© 2019 American Neurological Association.)
- Published
- 2019
- Full Text
- View/download PDF
34. Impact of a community-based naloxone distribution program on opioid overdose death rates.
- Author
-
Naumann RB, Durrance CP, Ranapurwala SI, Austin AE, Proescholdbell S, Childs R, Marshall SW, Kansagra S, and Shanahan ME
- Subjects
- Adolescent, Adult, Cost-Benefit Analysis, Delivery of Health Care economics, Drug Overdose drug therapy, Drug Overdose economics, Female, Humans, Male, Middle Aged, Naloxone economics, Narcotic Antagonists economics, North Carolina epidemiology, Opioid-Related Disorders drug therapy, Opioid-Related Disorders economics, Program Evaluation, Young Adult, Delivery of Health Care statistics & numerical data, Drug Overdose mortality, Naloxone therapeutic use, Narcotic Antagonists therapeutic use, Opioid-Related Disorders mortality
- Abstract
Background: In August 2013, a naloxone distribution program was implemented in North Carolina (NC). This study evaluated that program by quantifying the association between the program and county-level opioid overdose death (OOD) rates and conducting a cost-benefit analysis., Methods: One-group pre-post design. Data included annual county-level counts of naloxone kits distributed from 2013 to 2016 and mortality data from 2000-2016. We used generalized estimating equations to estimate the association between cumulative rates of naloxone kits distributed and annual OOD rates. Costs included naloxone kit purchases and distribution costs; benefits were quantified as OODs avoided and monetized using a conservative value of a life., Results: The rate of OOD in counties with 1-100 cumulative naloxone kits distributed per 100,000 population was 0.90 times (95% CI: 0.78, 1.04) that of counties that had not received kits. In counties that received >100 cumulative kits per 100,000 population, the OOD rate was 0.88 times (95% CI: 0.76, 1.02) that of counties that had not received kits. By December 2016, an estimated 352 NC deaths were avoided by naloxone distribution (95% CI: 189, 580). On average, for every dollar spent on the program, there was $2742 of benefit due to OODs avoided (95% CI: $1,237, $4882)., Conclusions: Our estimates suggest that community-based naloxone distribution is associated with lower OOD rates. The program generated substantial societal benefits due to averted OODs. States and communities should continue to support efforts to increase naloxone access, which may include reducing legal, financial, and normative barriers., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
35. Regulation of GLI1 by cis DNA elements and epigenetic marks.
- Author
-
Taylor R, Long J, Yoon JW, Childs R, Sylvestersen KB, Nielsen ML, Leong KF, Iannaccone S, Walterhouse DO, Robbins DJ, and Iannaccone P
- Subjects
- Animals, Binding Sites, Cell Cycle Proteins metabolism, Cell Line, Cells, Cultured, Feedback, Physiological, Hedgehog Proteins metabolism, Histones metabolism, Humans, Mice, Protein Binding, Transcription Factors metabolism, Transcriptional Activation, Zinc Finger Protein GLI1 metabolism, Enhancer Elements, Genetic, Epigenesis, Genetic, Zinc Finger Protein GLI1 genetics
- Abstract
GLI1 is one of three transcription factors (GLI1, GLI2 and GLI3) that mediate the Hedgehog signal transduction pathway and play important roles in normal development. GLI1 and GLI2 form a positive-feedback loop and function as human oncogenes. The mouse and human GLI1 genes have untranslated 5' exons and large introns 5' of the translational start. Here we show that Sonic Hedgehog (SHH) stimulates occupancy in the introns by H3K27ac, H3K4me3 and the histone reader protein BRD4. H3K27ac and H3K4me3 occupancy is not significantly changed by removing BRD4 from the human intron and transcription start site (TSS) region. We identified six GLI binding sites (GBS) in the first intron of the human GLI1 gene that are in regions of high sequence conservation among mammals. GLI1 and GLI2 bind all of the GBS in vitro. Elimination of GBS1 and 4 attenuates transcriptional activation by GLI1. Elimination of GBS1, 2, and 4 attenuates transcriptional activation by GLI2. Eliminating all sites essentially eliminates reporter gene activation. Further, GLI1 binds the histone variant H2A.Z. These results suggest that GLI1 and GLI2 can regulate GLI1 expression through protein-protein interactions involving complexes of transcription factors, histone variants, and reader proteins in the regulatory intron of the GLI1 gene. GLI1 acting in trans on the GLI1 intron provides a mechanism for GLI1 positive feedback and auto-regulation. Understanding the combinatorial protein landscape in this locus will be important to interrupting the GLI positive feedback loop and providing new therapeutic approaches to cancers associated with GLI1 overexpression., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
36. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4 R334X .
- Author
-
Levy E, Reger R, Segerberg F, Lambert M, Leijonhufvud C, Baumer Y, Carlsten M, and Childs R
- Subjects
- Amino Acid Substitution, Animals, Heterografts, Humans, Killer Cells, Natural cytology, Killer Cells, Natural transplantation, Mice, Mice, Inbred NOD, Mice, SCID, RNA, Messenger genetics, Receptors, CXCR4 genetics, Bone Marrow immunology, Gain of Function Mutation, Killer Cells, Natural immunology, RNA, Messenger immunology, Receptors, CXCR4 immunology, Transfection
- Abstract
Adoptive transfer of natural killer (NK) cells can induce remission in patients with relapsed/refractory leukemia and myeloma. However, to date, clinical efficacy of NK cell immunotherapy has been limited to a sub-fraction of patients. Here we show that steps incorporated in the ex vivo manipulation/production of NK cell products used for adoptive infusion, such as over-night IL-2 activation or cryopreservation followed by ex vivo expansion, drastically decreases NK cell surface expression of the bone marrow (BM) homing chemokine receptor CXCR4. Reduced CXCR4 expression was associated with dampened in vitro NK cell migration toward its cognate ligand stromal-derived factor-1α (SDF-1α). NK cells isolated from patients with WHIM syndrome carry gain-of-function (GOF) mutations in CXCR4 (CXCR4
R334X ). Compared to healthy donors, we observed that NK cells expanded from WHIM patients have similar surface levels of CXCR4 but have a much stronger propensity to home to BM compartments when adoptively infused into NOD- scid IL2Rgammanull (NSG) mice. Therefore, in order to augment the capacity of adoptively infused NK cells to home to the BM, we genetically engineered ex vivo expanded NK cells to express the naturally occurring GOF CXCR4R334X receptor variant. Transfection of CXCR4R334X -coding mRNA into ex vivo expanded NK cells using a clinically applicable method consistently led to an increase in cell surface CXCR4 without altering NK cell phenotype, cytotoxic function, or compromising NK cell viability. Compared to non-transfected and wild type CXCR4-coding mRNA transfected counterparts, CXCR4R334X -engineered NK cells had significantly greater chemotaxis toward SDF-1α in vitro . Importantly, expression of CXCR4R334X on expanded NK cells resulted in significantly greater BM homing following adoptive transfer into NSG mice compared to non-transfected NK cell controls. Collectively, these data suggest up-regulation of cell surface CXCR4R334X on ex vivo expanded NK cells via mRNA transfection represents a novel approach to improve homing and target NK cell-based immunotherapies to BM where hematological malignancies reside.- Published
- 2019
- Full Text
- View/download PDF
37. Silica/polycaprolactone nanofiber scaffold variants for human periosteal cell growth.
- Author
-
Burton CW, DiFeo Childs R, McClellan P, Yu Q, Bundy J, Gao M, Evans E, and Landis W
- Subjects
- Animals, Female, Heterografts, Humans, Male, Mice, Mice, Nude, Cells, Immobilized metabolism, Cells, Immobilized transplantation, Nanofibers chemistry, Osteoblasts metabolism, Osteoblasts transplantation, Periosteum metabolism, Periosteum transplantation, Polyesters chemistry, Silicon Dioxide chemistry, Tissue Scaffolds chemistry
- Abstract
Polycaprolactone (PCL) nanofiber scaffolds with attached cadaveric human periosteum or its cells were investigated in this study as a tissue-engineering approach to repair nonunion injuries of bone. Addition of silica nanoparticles (silica or nSiO
2 ) to PCL scaffolds was examined for effects on the growth of human periosteal cells in vitro and in vivo. Electrospun PCL nanofiber (nanoPCL) scaffolds were fabricated with different silica contents (0, 0.5, and 1.0 wt %) and utilized as substrates on which periosteal cells were seeded. Human periosteal cell growth analyzed in vitro over 21 days with a PrestoBlue viability assay increased as a function of culture time on each of the three different silica/nanoPCL scaffolds. Cadaveric periosteum attached to nanoPCL scaffolds with or without silica was wrapped around allograft bone and implanted for 10 or 20 weeks in athymic (nude) mice. Histological and immunohistochemical analyses of these experiments in vivo confirmed the presence of viable cells populating the constructs after their retrieval from host mice. Osterix, a marker for osteoblasts, increased in retrieved constructs over time and indicated remodeling of the underlying allograft bone. Summary results suggest that silica/nanoPCL scaffolds may be utilized as substrates for periosteal cell and tissue expansion to augment and support clinical applications for treatment and healing of bone defects, including segmental bone injuries and nonunions. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 791-801, 2019., (© 2018 Wiley Periodicals, Inc.)- Published
- 2019
- Full Text
- View/download PDF
38. Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib.
- Author
-
Borg MA, Shalabi RA, Childs R, and Wells BC
- Subjects
- Adult, Alopecia diagnosis, Alopecia etiology, Biopsy, Blood Transfusion, Chronic Disease, Graft vs Host Disease drug therapy, Humans, Janus Kinases, Male, Nitriles, Pyrimidines, Alopecia drug therapy, Graft vs Host Disease complications, Pyrazoles therapeutic use, Skin pathology, Transplant Recipients
- Published
- 2018
- Full Text
- View/download PDF
39. Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension.
- Author
-
Etzion O, Takyar V, Novack V, Gharib AM, Canales R, Adebogun A, Matsumoto E, Eccleston JL, Kleiner DE, Rosenzweig SD, Gunay-Aygun M, Uzel G, Fuss I, Childs R, Holland SM, Levy EB, Liang TJ, Heller T, and Koh C
- Abstract
Noncirrhotic portal hypertension (NCPH) is a rare disease that may lead to serious clinical consequences. Currently, noninvasive tools for the assessment of NCPH are absent. We investigated the utility of spleen and liver volumetrics as a marker of the presence and severity of portal hypertension in this population. A cohort of NCPH patients evaluated between 2003 and 2015 was retrospectively studied. The association of spleen and liver volumes with the hepatic venous pressure gradient (HVPG) level was evaluated using locally weighted scatterplot smoothing curves. A cohort of patients with viral hepatitis-related liver disease was used as controls. Of the 86 patients with NCPH evaluated during the study period, 75 (mean age, 35 ± 17; 73% males) were included in the final analysis. Patients with portal hypertension had significantly higher spleen and liver to body mass index (BMI) ratios compared to patients with HVPG <5 mm Hg (39.5 ± 27.9 versus 22.8 ± 10.6 cm
3 /kg/m2 , P = 0.003; 91.1 ± 40.1 versus 71.4 ± 16.7 cm3 /kg/m2 , P = 0.014, for spleen/BMI and liver/BMI, respectively). In contrast to the patients with viral hepatitis, a positive linear correlation was observed in the NCPH cohort between spleen/BMI and liver/BMI (above a cutoff of 25 and 80 cm3 /kg/m2 , respectively) and HVPG level. Additionally, only in the NCPH cohort was an increase in spleen/BMI range quartile predictive of a higher prevalence of portal hypertension and clinically significant portal hypertension (trend, P = 0.014 and 0.031, respectively). Conclusion: Spleen and liver volumetrics may have utility in the assessment of NCPH as a noninvasive biomarker that can be performed using routine radiologic examinations. Further studies are needed to validate these findings. ( Hepatology Communications 2018; 00:000-000).- Published
- 2018
- Full Text
- View/download PDF
40. Detection of toxigenic Clostridium difficile colonization in patients admitted to the hospital for chemotherapy or haematopoietic cell transplantation.
- Author
-
Vaughn JL, Balada-Llasat JM, Lamprecht M, Huang Y, Anghelina M, El Boghdadly Z, Bishop-Hill K, Childs R, Pancholi P, and Andritsos LA
- Subjects
- Adult, Aged, Aged, 80 and over, Carrier State microbiology, Clostridium Infections microbiology, Cross Infection microbiology, Female, Hospitals, Humans, Male, Middle Aged, Predictive Value of Tests, Sensitivity and Specificity, Young Adult, Bacteriological Techniques methods, Carrier State diagnosis, Clostridioides difficile isolation & purification, Clostridium Infections diagnosis, Cross Infection diagnosis, Diagnostic Tests, Routine methods, Hematologic Neoplasms complications
- Abstract
Increasing evidence suggests that asymptomatic carriers are an important source of healthcare-associated Clostridium difficile infection. However, it is not known which test for the detection of C. difficile colonization is most sensitive in patients with haematological malignancies. We performed a prospective cohort study of 101 patients with haematological malignancies who had been admitted to the hospital for scheduled chemotherapy or haematopoietic cell transplantation. Each patient provided a formed stool sample. We compared the performance of five different commercially available assays, using toxigenic culture as the reference method. The prevalence of toxigenic C. difficile colonization as determined by toxigenic culture was 14/101 (14 %). The Cepheid Xpert PCR C. difficile /Epi was the most sensitive test for the detection of toxigenic C. difficile colonization, with 93 % sensitivity and 99 % negative predictive value. Our findings suggest that the Xpert PCR C. difficile /Epi could be used to rule out toxigenic C. difficile colonization in this population.
- Published
- 2018
- Full Text
- View/download PDF
41. Low kV versus dual-energy virtual monoenergetic CT imaging for proven liver lesions: what are the advantages and trade-offs in conspicuity and image quality? A pilot study.
- Author
-
Hanson GJ, Michalak GJ, Childs R, McCollough B, Kurup AN, Hough DM, Frye JM, Fidler JL, Venkatesh SK, Leng S, Yu L, Halaweish AF, Harmsen WS, McCollough CH, and Fletcher JG
- Subjects
- Adult, Aged, Aged, 80 and over, Artifacts, Contrast Media, Female, Humans, Male, Middle Aged, Pilot Projects, Radiation Dosage, Radiographic Image Interpretation, Computer-Assisted, Retrospective Studies, Liver Neoplasms diagnostic imaging, Radiography, Dual-Energy Scanned Projection methods, Tomography, X-Ray Computed methods
- Abstract
Purpose: Single-energy low tube potential (SE-LTP) and dual-energy virtual monoenergetic (DE-VM) CT images both increase the conspicuity of hepatic lesions by increasing iodine signal. Our purpose was to compare the conspicuity of proven liver lesions, artifacts, and radiologist preferences in dose-matched SE-LTP and DE-VM images., Methods: Thirty-one patients with 72 proven liver lesions (21 benign, 51 malignant) underwent full-dose contrast-enhanced dual-energy CT (DECT). Half-dose images were obtained using single tube reconstruction of the dual-source SE-LTP projection data (80 or 100 kV), and by inserting noise into dual-energy projection data, with DE-VM images reconstructed from 40 to 70 keV. Three blinded gastrointestinal radiologists evaluated half-dose SE-LTP and DE-VM images, ranking and grading liver lesion conspicuity and diagnostic confidence (4-point scale) on a per-lesion basis. Image quality (noise, artifacts, sharpness) was evaluated, and overall image preference was ranked on per-patient basis. Lesion-to-liver contrast-to-noise ratio (CNR) was compared between techniques., Results: Mean lesion size was 1.5 ± 1.2 cm. Across the readers, the mean conspicuity ratings for 40, 45, and 50 keV half-dose DE-VM images were superior compared to other half-dose image sets (p < 0.0001). Per-lesion diagnostic confidence was similar between half-dose SE-LTP compared to half-dose DE-VM images (p ≥ 0.05; 1.19 vs. 1.24-1.32). However, SE-LTP images had less noise and artifacts and were sharper compared to DE-VM images less than 70 keV (p < 0.05). On a per-patient basis, radiologists preferred SE-LTP images the most and preferred 40-50 keV the least (p < 0.0001). Lesion CNR was also higher in SE-LTP images than DE-VM images (p < 0.01)., Conclusion: For the same applied dose level, liver lesions were more conspicuous using DE-VM compared to SE-LTP; however, SE-LTP images were preferred more than any single DE-VM energy level, likely due to lower noise and artifacts.
- Published
- 2018
- Full Text
- View/download PDF
42. Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition.
- Author
-
Cloud DH, Castillo T, Brinkley-Rubinstein L, Dubey M, and Childs R
- Subjects
- Criminal Law, Drug Overdose epidemiology, HIV Infections epidemiology, Hepatitis C epidemiology, Humans, Law Enforcement, Needle-Exchange Programs methods, North Carolina epidemiology, Political Systems, Public Health, Syringes, Drug Overdose prevention & control, HIV Infections prevention & control, Harm Reduction, Hepatitis C prevention & control, Needle-Exchange Programs legislation & jurisprudence, Substance Abuse, Intravenous therapy
- Abstract
Purpose of Review: Syringe access programs (SAPs) are cornerstone harm reduction interventions for combatting the national opioid epidemic. The goal of this paper is to describe effective advocacy strategies for enacting syringe decriminalization legislation to foster the expansion of SAPs in high-need areas amidst political opposition., Recent Findings: Decades or research shows that SAPs prevent the transmission of HIV among people who inject drugs (PWID) and are a cost-effective tool for linking PWID to medical care, health education, and social services. In the USA, state laws criminalizing distribution and possession of syringes impede the expansion of SAPs into areas where they are sorely needed. In 2016, North Carolina became the first state to legalize SAPs with a Republican super majority. This paper distills strategies for community organizations seeking to advance syringe decriminalization legislation in politically conservative states with histories of prioritizing punitive sanctions over public health responses to drug use.
- Published
- 2018
- Full Text
- View/download PDF
43. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
- Author
-
Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, and Wiestner A
- Subjects
- Adenine analogs & derivatives, Adult, Aged, Aged, 80 and over, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Bone Marrow metabolism, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Male, Middle Aged, Neoplasm Staging, Neoplasm, Residual, Piperidines, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Pyrazoles administration & dosage, Pyrazoles adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Treatment Outcome, Antineoplastic Agents therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Protein Kinase Inhibitors therapeutic use, Pyrazoles therapeutic use, Pyrimidines therapeutic use
- Abstract
The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were evaluated in a phase 2 study; 51 patients had TP53 aberration (TP53 cohort) and 35 were enrolled because of age 65 years or older (elderly cohort). Both cohorts included patients with treatment-naive (TN) and relapsed/refractory (RR) CLL. With the median follow-up of 4.8 years, 49 (57.0%) of 86 patients remain on study. Treatment was discontinued for progressive disease in 20 (23.3%) patients and for adverse events in 5 (5.8%). Atrial fibrillation occurred in 18 (20.9%) patients for a rate of 6.4 per 100 patient-years. No serious bleeding occurred. The overall response rate at 6 months, the primary study endpoint, was 95.8% for the TP53 cohort (95% confidence interval, 85.7%-99.5%) and 93.9% for the elderly cohort (95% confidence interval, 79.8%-99.3%). Depth of response improved with time: at best response, 14 (29.2%) of 48 patients in the TP53 cohort and 9 (27.3%) of 33 in the elderly cohort achieved a complete response. Median minimal residual disease (MRD) in peripheral blood was 3.8 × 10
-2 at 4 years, with MRD-negative (<10-4 ) remissions in 5 (10.2%) patients. In the TP53 cohort, the estimated 5-year progression-free survival (PFS) was 74.4% in TN-CLL compared with 19.4% in RR-CLL ( P = .0002), and overall survival (OS) was 85.3% vs 53.7%, respectively ( P = .023). In the elderly cohort, the estimated 5-year PFS and OS in RR-CLL were 64.8% and 71.6%, respectively, and no event occurred in TN-CLL. Long-term administration of ibrutinib was well tolerated and provided durable disease control for most patients. This trial was registered at www.clinicaltrials.gov as #NCT01500733., (© 2018 by The American Society of Hematology.)- Published
- 2018
- Full Text
- View/download PDF
44. Access to Syringe Services Programs - Kentucky, North Carolina, and West Virginia, 2013-2017.
- Author
-
Bixler D, Corby-Lee G, Proescholdbell S, Ramirez T, Kilkenny ME, LaRocco M, Childs R, Brumage MR, Settle AD, Teshale EH, and Asher A
- Subjects
- HIV Infections epidemiology, HIV Infections prevention & control, Hepatitis C epidemiology, Hepatitis C prevention & control, Humans, Kentucky epidemiology, North Carolina epidemiology, Substance Abuse, Intravenous complications, West Virginia epidemiology, Health Services Accessibility legislation & jurisprudence, Needle-Exchange Programs legislation & jurisprudence
- Abstract
The Appalachian region of the United States is experiencing a large increase in hepatitis C virus (HCV) infections related to injection drug use (IDU) (1). Syringe services programs (SSPs) providing sufficient access to safe injection equipment can reduce hepatitis C transmission by 56%; combined SSPs and medication-assisted treatment can reduce transmission by 74% (2). However, access to SSPs has been limited in the United States, especially in rural areas and southern and midwestern states (3). This report describes the expansion of SSPs in Kentucky, North Carolina, and West Virginia during 2013-August 1, 2017. State-level data on the number of SSPs, client visits, and services offered were collected by each state through surveys of SSPs and aggregated in a standard format for this report. In 2013, one SSP operated in a free clinic in West Virginia, and SSPs were illegal in Kentucky and North Carolina; by August 2017, SSPs had been legalized in Kentucky and North Carolina, and 53 SSPs operated in the three states. In many cases, SSPs provide integrated services to address hepatitis and human immunodeficiency virus (HIV) infection, overdose, addiction, unintended pregnancy, neonatal abstinence syndrome, and other complications of IDU. Prioritizing development of SSPs with sufficient capacity, particularly in states with counties vulnerable to epidemics of hepatitis and HIV infection related to IDU, can expand access to care for populations at risk., Competing Interests: No conflicts of interest were reported.
- Published
- 2018
- Full Text
- View/download PDF
45. Tools to improve planning, implementation, monitoring, and evaluation of complementary feeding programmes.
- Author
-
Untoro J, Childs R, Bose I, Winichagoon P, Rudert C, Hall A, and de Pee S
- Subjects
- Developing Countries, Food Quality, Growth Disorders prevention & control, Humans, Infant, Nutrition Policy, Nutritive Value, Poverty, Diet, Health Plan Implementation, Infant Food, Infant Nutritional Physiological Phenomena, Program Development, Program Evaluation
- Abstract
Adequate nutrient intake is a prerequisite for achieving good nutrition status. Suboptimal complementary feeding practices are a main risk factor for stunting. The need for systematic and user-friendly tools to guide the planning, implementation, monitoring, and evaluation of dietary interventions for children aged 6-23 months has been recognized. This paper describes five tools, namely, ProPAN, Optifood, Cost of the Diet, Fill the Nutrient Gap, and Monitoring Results for Equity System that can be used in different combinations to improve situation analysis, planning, implementation, monitoring, or evaluation approaches for complementary feeding in a particular context. ProPAN helps with development of strategies and activities designed to change the behaviours of the target population. Optifood provides guidance for developing food-based recommendations. The Cost of the Diet can provide insight on economic barriers to accessing a nutritious and balanced diet. The Fill the Nutrient Gap facilitates formulation of context-specific policies and programmatic approaches to improve nutrient intake, through a multistakeholder process that uses insights from linear programming and secondary data. The Monitoring Results for Equity System helps with analysis of gaps, constraints, and determinants of complementary feeding interventions and adoption of recommended practices especially in the most vulnerable and deprived populations. These tools, and support for their use, are readily available and can be used either alone and/or complementarily throughout the programme cycle to improve infant and young child-feeding programmes at subnational and national levels., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
46. Developing sustainable research careers for KL2 scholars: The importance of an inclusive environment and mentorship.
- Author
-
Byington CL, Rothwell E, Matheson T, Childs R, Wachs E, Rocha R, Murtaugh M, Turok D, Letsou A, Shakib J, Hess R, and Dere W
- Abstract
Introduction: The National Clinical and Translational Science Award (CTSA) Consortium 2.0 has developed common metrics as a collaborative project for all participating sites. Metrics address several important aspects and functions of the consortium, including workforce development. The first workforce development metrics to be proposed for all CTSA hubs include the proportion of CTSA-supported trainees and scholars with sustainable careers in translational research and the diversity and inclusiveness of programs., Methods and Results: The University of Utah Center for Clinical and Translational Science (CCTS), a CTSA hub, has been actively engaged in mentoring translational scientists for the last decade. We have developed programs, processes, and institutional policies that support translational scientists, which have resulted in 100% of our KL2 scholars remaining engaged in translational science and in increasing the inclusion of individuals under-represented in medicine in our research enterprise. In this paper, we share details of our program and what we believe are evidence-based best practices for developing sustainable translational research careers for all aspiring junior faculty members., Conclusions: The University of Utah Center for Clinical and Translational Science has been integral in catalyzing interactions across the campus to reverse the negative trends seen nationally in sustaining clinician scientists. Our programs and processes can serve as a model for other institutions seeking to develop translational scientists.
- Published
- 2017
- Full Text
- View/download PDF
47. Response to: 'How effective are selection methods in medical education? A systematic review'.
- Author
-
Adam J, Bore M, Childs R, Dunn J, McKendree J, Munro D, and Powis D
- Subjects
- Humans, Education, Medical
- Published
- 2017
- Full Text
- View/download PDF
48. Cost of the Diet: a method and software to calculate the lowest cost of meeting recommended intakes of energy and nutrients from local foods.
- Author
-
Deptford A, Allieri T, Childs R, Damu C, Ferguson E, Hilton J, Parham P, Perry A, Rees A, Seddon J, and Hall A
- Abstract
Background: When food is available, the main obstacle to access is usually economic: people may not be able to afford a nutritious diet, even if they know what foods to eat. The Cost of the Diet method and software was developed to apply linear programming to better understand the extent to which poverty may affect people's ability to meet their nutritional specifications. This paper describes the principles of the method; the mathematics underlying the linear programming; the parameters and assumptions on which the calculations are based; and then illustrates the output of the software using examples taken from assessments., Results: The software contains five databases: the energy and nutrient content of foods; the energy and nutrient specifications of individuals; predefined groups of individuals in typical households; the portion sizes of foods; and currency conversion factors. Data are collected during a market survey to calculate the average cost of foods per 100 g while focus group discussions are used to assess local dietary habits and preferences. These data are presented to a linear programming solver within the software which selects the least expensive combination of local foods for four standard diets that meet specifications for: energy only; energy and macronutrients; energy, macronutrients and micronutrients; and energy, macronutrients and micronutrients but with constraints on the amounts per meal that are consistent with typical dietary habits. Most parameters in the software can be modified by users to examine the potential impact of a wide range of theoretical interventions. The output summarises for each diet the costs, quantity and proportion of energy and nutrient specifications provided by all the foods selected for a given individual or household by day, week, season and year. When the cost is expressed as a percentage of income, the affordability of the diet can be estimated., Conclusions: The Cost of the Diet method and software could be used to inform programme design and behaviour change communication in the fields of nutrition, food security, livelihoods and social protection as well as to influence policies and advocacy debates on the financial cost of meeting energy and nutrient specifications., Competing Interests: The authors declare that they have no competing interests., (© The Author(s). 2017.)
- Published
- 2017
- Full Text
- View/download PDF
49. Haploidentical cord transplantation-The best of both worlds.
- Author
-
van Besien K and Childs R
- Subjects
- Fetal Blood, Graft vs Host Disease immunology, Hematologic Neoplasms immunology, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Transplantation Conditioning, Cord Blood Stem Cell Transplantation, Haploidy
- Abstract
Haploidentical (haplo)-cord transplantation combines infusion of an umbilical cord blood (UCB) unit with CD34-selected cells usually from human leukocyte antigen (HLA) mismatched donors. Initial rapid count recovery from the haplo-hematopoietic progenitors, is gradually replaced by durable engraftment from UCB progenitors. UCB grafts used for haplo-cord are smaller, but better matched than those required for single or double UCB stem cell transplant (SCT). More than 200 patients with hematological malignancies have been transplanted. Median age was 54 years (range 17-74) and 77 were over age 60. One-year survival was 64% for patients with intermediate- and low-risk disease, with no deaths beyond 2 years. In high-risk disease, 1-year survival was 44%. In a comparison with patients undergoing double UCB SCT, haplo-cord transplant resulted in faster hematopoietic recovery, lower rates of acute and chronic graft-versus-host disease (GVHD), lower rates of disease recurrence, and improved GVHD- and relapse-free survival (GRFS). Excellent results were also reported for patients with aplastic anemia where 18 of 21 patients had sustained cord blood engraftment. Rates of GVHD and of disease recurrence after haplo-cord are encouraging. However, in the approximately 10% of patients with failure of the UCB graft disease recurrence is high, supporting the important role of UCB-mediated graft-versus-leukemia (GVL). Ongoing efforts are aimed at identifying determinants of UCB engraftment, at reducing rates of disease recurrence in high risk patients and at optimizing dose and schedule of ATG -necessary to avoid early haplo-graft rejection, but also contributing to early post-transplant immunocompromise. For those lacking haploidentical donors, unrelated donors have been successfully utilized., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
50. Alternative Donor Allogeneic Transplants: Introduction.
- Author
-
Childs R and Blaise D
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.